Listen to Story Popular anti-diabetes and obesity drug Mounjaro has been launched in India, by the US-based pharmaceutical giant Eli Lilly, after receiving marketing authorisation from India's drug regulator - the Central Drugs Standard Control Organisation (CDSCO). Mounjaro is used for type 2 diabetes or diabetes mellitus and weight management. The drug is now available in a single-dose vial that works by activating two key hormones, GIP and GLP-1, which help control blood sugar levels and appetite.
It is meant to be used along with a healthy diet and regular exercise. The prescription drug is recommended for: Obesity and type 2 diabetes are rising rapidly in India, making them major health challenges. Winselow Tucker, President of Lilly India, said the company is working with the government and healthcare industry to raise awareness and improve treatment options.
"Our goal is to help people with obesity and diabetes live healthier lives. The launch of Mounjaro is part of our commitment to bringing innovative medicines to India," he said. Mounjaro is used for type 2 diabetes or diabetes mellitus and weight management.
(Photo: Getty Images) In July 2024, a subject expert committee under India's apex drug regulator, had given a green light to Lilly's tirzepatide, the active ingredient in their popular drugs Mounjaro and Zepbound. Mounjaro was tested in two major global studies: SURMOUNT-1 (for weight loss): In a study of 2,539 adults with obesity or excess weight, people who t.
